Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 235,000 Shares of Stock

01 Jun 2026, 23:50 by Danessa Lincoln · The Markets Daily

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 235,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the transaction, the director directly owned 2,830,452 shares of the company’s stock, valued at $463,146,860.76. This represents a 7.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Illumina Price Performance

NASDAQ:ILMN traded up $1.44 on Monday, reaching $164.40. 2,190,450 shares of the company’s stock traded hands, compared to its average volume of 1,870,323. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The stock has a 50-day simple moving average of $133.73 and a 200-day simple moving average of $132.09. The firm has a market cap of $24.87 billion, a PE ratio of 29.89, a P/E/G ratio of 2.70 and a beta of 1.50. Illumina, Inc. has a 12 month low of $78.79 and a 12 month high of $165.97.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Capital World Investors raised its position in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares during the period. State Street Corp boosted its holdings in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after purchasing an additional 190,324 shares during the period. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after buying an additional 130,139 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ILMN. Canaccord Genuity Group decreased their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. UBS Group reissued a “neutral” rating and set a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Finally, Piper Sandler decreased their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus target price of $138.38.

Read Our Latest Stock Analysis on ILMN

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.